| Date | Title | | | 05/14/12 | Isis Pharmaceuticals to Present A General Corporate Update at Its 2012 Annual Meeting of Stockholders and Open House|
CARLSBAD, Calif., May 14, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a general corporate update in conjunction with its 2012 Annual Meeting of Stockholders and Open House on Thursday, June 7 at 2:10 p.m. Pacific Time in Carlsbad, CA.
The agenda for the meeting is as follows:
2:00 p.m. – 2:10 p.m. Annual Meeting of Stockholders (only for stockholders of record as of April 9, 2012)
2:10 p... |
|  | | 05/09/12 | Isis Pharmaceuticals to Present at the Bank of America Merrill Lynch 2012 Health Care Conference|
CARLSBAD, Calif., May 9, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at Bank of America Merrill Lynch's 2012 Health Care Conference on Tuesday, May 15, 2012 at 2:20 p.m. PT at the Encore at the Wynn in Las Vegas, NV.
A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site, www.isispharm.com. ... |
| | | 05/08/12 | Isis Reports Financial Results and Highlights for First Quarter 2012| - Conference Call Webcast Tuesday, May 8, 4:30 p.m. ET at www.isispharm.com
CARLSBAD, Calif., May 8, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today reported a pro forma net operating loss (NOL) of $16.2 million for the first quarter of 2012 compared to a pro forma NOL of $13.4 million for the same period in 2011. The Company ended the first quarter of 2012 with nearly $334 million in cash.
"Already in 2012, we have had multiple important accomplishments. Our partn... |
| | | 05/04/12 | Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia| Conference Call Webcast and Slide Presentation, Friday, May 4 at 11:00 a.m. EDT at www.isispharm.com
CARLSBAD, Calif., May 4, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced the initiation of a Phase 2 study evaluating ISIS-APOCIIIRx in patients with hypertriglyceridemia. Hypertriglyceridemia, a condition characterized by high levels of triglycerides, is often associated with premature coronary artery disease and pancreatitis. Patients with severe hypertriglyceride... |
| |
|
